Transforming vaccinology.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
19 Sep 2024
Historique:
received: 24 01 2024
revised: 24 06 2024
accepted: 12 07 2024
medline: 21 9 2024
pubmed: 21 9 2024
entrez: 20 9 2024
Statut: ppublish

Résumé

The COVID-19 pandemic placed the field of vaccinology squarely at the center of global consciousness, emphasizing the vital role of vaccines as transformative public health tools. The impact of vaccines was recently acknowledged by the award of the 2023 Nobel Prize in Physiology or Medicine to Katalin Kariko and Drew Weissman for their seminal contributions to the development of mRNA vaccines. Here, we provide a historic perspective on the key innovations that led to the development of some 27 licensed vaccines over the past two centuries and recent advances that promise to transform vaccines in the future. Technological revolutions such as reverse vaccinology, synthetic biology, and structure-based design transformed decades of vaccine failures into successful vaccines against meningococcus B and respiratory syncytial virus (RSV). Likewise, the speed and flexibility of mRNA vaccines profoundly altered vaccine development, and the advancement of novel adjuvants promises to revolutionize our ability to tune immunity. Here, we highlight exciting new advances in the field of systems immunology that are transforming our mechanistic understanding of the human immune response to vaccines and how to predict and manipulate them. Additionally, we discuss major immunological challenges such as learning how to stimulate durable protective immune response in humans.

Identifiants

pubmed: 39303685
pii: S0092-8674(24)00781-5
doi: 10.1016/j.cell.2024.07.021
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
mRNA Vaccines 0

Types de publication

Journal Article Review Historical Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5171-5194

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests G.A. is an employee of Moderna. R.R. has been an employee of GSK. B.P. has served or is serving on the External Immunology Network of GSK and on the scientific advisory boards of Sanofi, Medicago, CircBio, and Boehringer Ingelheim.

Auteurs

Rino Rappuoli (R)

Biotecnopolo di Siena Foundation, Siena, Italy. Electronic address: rino.rappuoli@biotecnopolo.it.

Galit Alter (G)

Moderna Therapeutics, Cambridge, MA 02139, USA. Electronic address: galit.alter@modernatx.com.

Bali Pulendran (B)

Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: bpulend@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH